Lannett Co Inc (LCI) Given Consensus Recommendation of “Hold” by Brokerages

Lannett Co Inc (NYSE:LCI) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $27.50.

A number of equities research analysts have commented on LCI shares. Zacks Investment Research upgraded Lannett Co from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research report on Saturday, April 22nd. BMO Capital Markets started coverage on Lannett Co in a research report on Monday, May 1st. They issued a “market perform” rating and a $29.00 target price on the stock. Robert W. Baird restated an “outperform” rating and issued a $18.00 target price on shares of Lannett Co in a research report on Wednesday, May 3rd. Roth Capital set a $27.00 target price on Lannett Co and gave the company a “buy” rating in a research report on Tuesday, May 2nd. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Lannett Co in a research report on Tuesday, May 2nd.

Lannett Co (NYSE LCI) traded up 0.31% during trading on Monday, hitting $16.20. The stock had a trading volume of 302,382 shares. Lannett Co has a 12 month low of $15.75 and a 12 month high of $39.99. The company’s 50 day moving average is $20.12 and its 200-day moving average is $21.31. The company’s market cap is $603.13 million.

TRADEMARK VIOLATION NOTICE: This story was first published by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/lannett-company-inc-lci-given-average-rating-of-hold-by-analysts-updated-updated-updated.html.

Several large investors have recently modified their holdings of the stock. State of Alaska Department of Revenue boosted its stake in shares of Lannett Co by 77.6% in the second quarter. State of Alaska Department of Revenue now owns 5,753 shares of the company’s stock worth $117,000 after buying an additional 2,513 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in Lannett Co by 4.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 6,940 shares of the company’s stock valued at $142,000 after buying an additional 300 shares during the last quarter. Mason Street Advisors LLC boosted its position in Lannett Co by 7.5% in the first quarter. Mason Street Advisors LLC now owns 6,870 shares of the company’s stock valued at $154,000 after buying an additional 482 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in Lannett Co by 49.6% in the second quarter. BNP Paribas Arbitrage SA now owns 9,235 shares of the company’s stock valued at $188,000 after buying an additional 3,061 shares during the last quarter. Finally, Airain ltd bought a new position in Lannett Co during the first quarter valued at approximately $205,000. 95.14% of the stock is owned by institutional investors and hedge funds.

About Lannett Co

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Analyst Recommendations for Lannett Co (NYSE:LCI)

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply